Kidney Cancer

Articles

The combination of lenvatinib plus pembrolizumab showed antitumor activity and a manageable safety profile for treatment-naïve or previously treated patients with metastatic renal cell carcinoma.

Lenvatinib Plus Pembrolizumab Demonstrates Antitumor Activity, Maintains Safety in Metastatic RCC

Podcasts

Robert A. Figlin, MD, spoke with CancerNetwork® about emerging second-line therapies as the paradigm of first-line treatment evolves for patients with metastatic clear cell renal cell carcinoma.

Oncology Peer Review On-The-Go: Considering Second-Line Treatment Amidst Evolving Frontline Landscape for Clear Cell RCC

Videos

Robert A. Figlin, MD, highlights toxicities that patients with renal cell carcinoma experience while on cabozantinib.

Robert A. Figlin, MD, on Adverse Effects of Cabozantinib in RCC

New findings indicate that historically underserved patient populations with renal cell carcinoma are more likely to receive non–guidance-based treatment.

Increased Rates of Non–Guidance-Based Treatment Identified in Female, Black, and Hispanic Populations with RCC

At ASCO 2021, Chung-Han Lee, MD, PhD, discussed an ongoing trial looking at pembrolizumab plus lenvatinib as frontline therapy for non–clear cell renal cell carcinoma.

Chung-Han Lee, MD, PhD, on TKI/IO Combination Therapy for Non–Clear Cell RCC

CancerNetwork® sat down with Robert A. Figlin, MD, at the 2021 ASCO Annual Meeting to discuss the results of the KEYNOTE-564 trial with adjuvant pembrolizumab in patients with resected clear cell renal cell carcinoma. 

Robert A. Figlin, MD, Spotlights Key Findings With Adjuvant Pembrolizumab in Resected Clear Cell RCC From ASCO 2021

Benjamin A. Teply, MD, considers the optimal treatment of renal cell carcinoma in a peer perspective accompanying an article by Tiffany Y. Shaw, MD, and colleagues. 

Navigating an Optimal Treatment Course for Advanced Kidney Cancer

Motzer discussed time to deterioration end points for patients with advanced renal cell carcinoma treated with pembrolizumab and lenvatinib in the first-line setting.

Robert J. Motzer, MD, on Main HRQOL Takeaways From Phase 3 CLEAR Trial

In recent years, first-line therapies for metastatic renal cell carcinoma (mRCC) have shifted to a combination of immune checkpoint inhibitors or a combination of antiangiogenesis tyrosine kinase inhibitors (TKIs) and immunotherapy. This has led to a need to address standard-of-care treatment in the second-line setting.

Second-Line Therapies in the Changing Landscape of First-Line Therapies for Metastatic Clear Cell Renal Cell Cancer

CancerNetwork® sat down with Robert A. Figlin, MD, at the 2021 ASCO Annual Meeting to discuss results of the CANTATA trial of cabozantinib with or without telaglenastat.

Renal Cell Carcinoma | Topics